In dedicated phase 2 trials, the use of sorafenib and regorafenib was associated with response rates of 23% and 17.4%, respectively, confirming that oral anti‐VEGF agents exert clinical activity against advanced angiosarcoma.23, 24. This evidence concerns the gene VEGFA and angiosarcoma.